Key Developments For MAKO Surgical Corp.
MAKO Surgical Corp. (MAKO.O) (Consolidated Issue listed on NASDAQ Global Market)
MAKO Surgical Corp. Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters' Over-Allotment Option
MAKO Surgical Corp. announced that it has closed its public offering of 8,050,000 shares of its common stock, which includes 1,050,000 shares issued as a result of the underwriters' exercise of their over-allotment option. Piper Jaffray & Co. acted as the sole book-running manager for the offering and Leerink Swann LLC acted as co-manager. The Company plans to use the net proceeds of approximately $54.4 million, after deducting underwriting discounts and commissions and estimated expenses of the offering, to support commercialization, sales, marketing and general administrative activities, for research and product development activities and to fund working capital and other general corporate purposes.
MAKO Surgical Corp. Announces Pricing of Public Offering of Common Stock
MAKO Surgical Corp. announced that it has priced its public offering of 7,000,000 shares of its common stock at a price to the public of $7.25 per share. The closing of the offering is expected to take place on August 19, 2009. Piper Jaffray & Co. acted as the sole book-running manager for the offering and Leerink Swann LLC acted as co-manager. Assuming no exercise of the underwriters' over-allotment option, MAKO expects to receive gross proceeds from the offering of approximately $50.8 million. MAKO will use the net proceeds of approximately $47.2 million after deducting underwriting discounts and commissions and estimated expenses of the offering to support commercialization, sales, marketing and general administrative activities, for research and product development activities and to fund working capital and other general corporate purposes.
MAKO Surgical Corp. Announces Common Stock Offering
MAKO Surgical Corp. announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole book running manager for the offering and Leerink Swann LLC is acting as co manager. This offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on May 18, 2009, which became effective on May 26, 2009.
MAKO Surgical Corp. Files Shelf Registration Statement
MAKO Surgical Corp. announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission. The shelf registration statement, when declared effective by the Securities and Exchange Commission, will allow MAKO the flexibility to offer and sell from time to time over a three-year period, in one or more public offerings, up to $50 million of debt securities, common stock, preferred stock, warrants, stock purchase contracts, stock purchase units, or any combination thereof. The terms of any such offerings will be established at the time of the offering, will be subject to market conditions and will be described in a supplement to the prospectus.
MAKO Surgical Corp. Receives FDA Clearance To Market Both Its Version 2.0 Tactile Guidance System And Its Bicompartmental Knee Resurfacing Implant System
MAKO Surgical Corp. announced that it received two 510(k) clearances from the US Food and Drug Administration (FDA) to market both the Company's proprietary Version 2.0 Tactile Guidance System (TGS), branded as the MAKO RIO, and its bicompartmental knee resurfacing implant system, branded as RESTORIS MCK. MAKO currently expects to commercially launch both the RIO system and the RESTORIS MCK system in the first half of 2009.
